---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125385"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:51:23.126159+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Clearside Q3 2024 net loss $7.7M; ODYSSEY Phase 2b wet AMD trial hits all endpoints

## Summary
- Net loss of $7.7M ($0.10 per share) vs. $9.3M ($0.15) in Q3 2023; revenue $1.0M, up from $0.9M.
- ODYSSEY Phase 2b of suprachoroidal CLS-AX in wet AMD met all primary and secondary outcomes with extended duration.
- Cash, equivalents and short-term investments $23.6M as of Sep 30, 2024; runway into Q3 2025.
- Asia-Pacific partner Arctic Vision licensed ARVN001 to Santen for China; Phase 3 UME data positive.
- Tony Gibney appointed Chair of Board; REGENXBIO advances ABBV-RGX-314 via SCS Microinjector toward pivotal trial.

## SEC filing metadata
- accession: 0000950170-24-125385
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017024125385/0000950170-24-125385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017024125385/clsd-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125385
- JSON: https://secwatch.observer/filing/0000950170-24-125385.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.